AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioXcel Therapeutics CEO to speak at Canaccord Genuity Growth Conference.
ByAinvest
Monday, Aug 11, 2025 7:04 am ET1min read
BioXcel Therapeutics announced that CEO Vimal Mehta will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Aug. 12, 2025, at 12 p.m. ET. The webcast will be available on the company's website for 90 days. BioXcel Therapeutics is a biopharmaceutical company using AI to develop transformative medicines in neuroscience.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company leveraging artificial intelligence (AI) to develop transformative medicines in neuroscience, has announced that its CEO, Vimal Mehta, Ph.D., will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 12 p.m. ET. The event will take place in Boston, and investors can access the webcast through the company's website under the "Events & Presentations" page. The replay will be available for 90 days [1].BioXcel Therapeutics is committed to re-innovating drugs using big data and proprietary machine learning algorithms. Its wholly owned subsidiary, OnkosXcel Therapeutics, focuses on developing medicines in immuno-oncology. The company's innovative approach aims to identify new therapeutic indications for existing approved drugs and clinically validated product candidates [2].
The fireside chat will provide an opportunity for investors and industry professionals to hear directly from CEO Vimal Mehta about BioXcel Therapeutics' progress, future plans, and the potential of AI in drug discovery and development. The event is expected to shed light on the company's pipeline, including product candidates such as IGALMI®, BXCL501, BXCL502, BXCL701, and BXCL702.
References:
[1] https://www.globenewswire.com/news-release/2025/08/11/3130781/0/en/BioXcel-Therapeutics-to-Participate-in-Canaccord-Genuity-45th-Annual-Growth-Conference.html
[2] https://www.stocktitan.net/news/BTAI/bio-xcel-therapeutics-to-participate-in-canaccord-genuity-45th-ijfsv8m1ht4x.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet